Remove agencies food-and-drug-administration
article thumbnail

Pharma Cos., FDA Debate 'Same Drug' In Orphan Drug Case

IP Law 360

Food and Drug Administration faced off in D.C. federal court Friday over allegations that the federal agency wrongly approved a treatment that rivals Jazz Pharma's narcolepsy drug despite Jazz's exclusivity rights under the Orphan Drug Act. Two pharmaceutical companies and the U.S.

52
article thumbnail

Judge Denies Injunction For Tyvaso Drug Competitor

IP Law 360

Food and Drug Administration from approving a new competitor to its blockbuster pulmonary hypertension medication Tyvaso, saying the company was effectively seeking to challenge an agency action before the FDA made one. federal judge Friday denied drugmaker United Therapeutics Corp.'s

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

USPTO-FDA Listening Session: Patient Advocates Want Access, Patent Advocates Want Evidence

IP Watchdog

Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) today jointly held an all-day listening session featuring speakers from patient advocacy and industry groups, academia, and brand and generic pharmaceutical companies who weighed in on the relationship between patents and affordable access to medicines.

Patent 126
article thumbnail

FTC Disputes Patent Listings of 10 Brand Drug Makers as Improperly Listed in FDA’s Orange Book

JD Supra Law

On November 7, 2023, the Federal Trade Commission (FTC) sent notice letters1 to 10 brand drug manufacturers of drug-device combination products, including drugs delivered by asthma inhalers, epinephrine autoinjectors, and cyclosporine dropper bottles. Food and Drug Administration (FDA) regarding more than 60 unique.

article thumbnail

Biosimilars 2022 Year in Review

JD Supra Law

Food and Drug Administration approval of biosimilars in new therapeutic areas, additional interchangeable designations, and litigation relating to biosimilars of more recent biologics. Regulatory agencies and legislators also renewed their focus on access to lower-cost biologics, including biosimilars.

article thumbnail

FDA Drug Approvals Don't Include Impurities, DC Circ. Rules

IP Law 360

Food and Drug Administration's win in Sandoz Inc.'s s lawsuit challenging the agency's decision to give rival Sanofi exclusivity to its multiple sclerosis drug, Aubagio, rejecting Sandoz's claim that the FDA already approved the drug's active ingredient as an impurity in another drug.

75
article thumbnail

PMPRB releases report on expensive drugs for rare diseases

JD Supra Law

On January 11, 2022, the Patented Medicine Prices Review Board (PMPRB) released a report entitled Expensive Drugs for Rare Diseases: Canadian Trends and International Comparisons, 2011-2020 as part of the National Prescription Drug Utilization Information System (NPDUIS) initiative. By: Smart & Biggar